An accompanying research for the Phase II study of nivolumab + bevacizumab + paclitaxel in patients with HER2-negative metastatic breast cancer:WJOG9917B(WJOG9917BTR)

Trial Profile

An accompanying research for the Phase II study of nivolumab + bevacizumab + paclitaxel in patients with HER2-negative metastatic breast cancer:WJOG9917B(WJOG9917BTR)

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms WJOG9917BTR
  • Most Recent Events

    • 21 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top